Eam Investors, LLC 89bio, Inc. Transaction History

Eam Investors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$14.15 - $22.03 $990,245 - $1.54 Million	-69,982 Reduced 24.43%	216,438 $4.1 Million
Q1 2023 Jul 12, 2023	BUY	$10.48 - $16.94 $3 Million - $4.85 Million	286,420 New	286,420 $4.36 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $470,441 - $1.08 Million	85,225 Added 44.69%	275,943 $3.51 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $575,968 - $1.34 Million	190,718 New	190,718 $1.1 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.